Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2309-2319

  Pastuskovas, Cinthia V ^a   Mallet, William ^a   Clark, Suzanna ^a   Kenrick, Margaret ^a   Majidy, Mohammed ^a   Schweiger, Michelle ^a   Van Hoy, Marjie ^a   Tsai, Siao Ping ^a   Bennett, Gregory ^a   Shen, Ben Quan ^a   Ross, Sarajane ^a   Fielder, Paul ^a   Khawli, Leslie ^a   Tibbitts, Jay ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3A5 ANTIBODY; 3A5 ANTIBODY I 125; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CANCER ANTIBODY; IODINE 125; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; TISSUE DISTRIBUTION; WHOLE BODY AUTORADIOGRAPHY;

ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; CA-125 ANTIGEN; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; TISSUE DISTRIBUTION;

MUS;

EID: 78649530346     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034330     Document Type: Article

References (37)

1. American Cancer Society (2007) Cancer Facts & Figures, American Cancer Society, Atlanta, GA.
2. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887.
3. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, and Mills GB (1998) CA 125: the past and the future. Int J Biol Markers 13:179-187.
4. Beck EP, Moldenhauer A, Merkle E, Kiesewetter F, Jäger W, Wildt L, and Lang N (1998) CA 125 production and release by ovarian cancer cells in vitro. Int J Biol Markers 13:200-206. (Pubitemid 29178549)
5. Berek JS, Taylor PT, and Nicodemus CF (2008) CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31:207-214.
6. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, and Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369.
7. Busch U, Heinzel G, and Nehmiz G (2000) Precision of measurement of tissue concentrations by RLG. Regul Toxicol Pharmacol 31:S45-S50.
8. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, et al. (2007) Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 67:4924-4932.
9. Davies Q, Perkins AC, Frier M, Watson S, Lalani E, and Symonds EM (1997) The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur J Nucl Med 24:206-209.
10. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, and Swenerton KD (2005) A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15:1023-1034.
11. Hagan PL, Halpern SE, Chen A, Krishnan L, Frincke J, Bartholomew RM, David GS, and Carlo D (1985) In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J Nucl Med 26:1418-1423. (Pubitemid 16063024)
12. Haisma HJ, Battaile A, Stradtman EW, Knapp RC, and Zurawski VR Jr (1987) Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer. Int J Cancer 40:758-762.
13. Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5:292-302.
14. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
15. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932.
16. Kobayashi H, Sakahara H, Saga T, Hosono M, Shirato M, Kanda H, Ishibashi K, Watanabe T, Endo K, and Ishiwata I (1993) A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol Immunother 37:143-149.
17. Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, Seki E, Matsuda T, Motoda Y, Kobayashi A, et al. (2004) Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem 279:13174-13182.
18. McQuarrie SA, Baum RP, Niesen A, Madiyalakan R, Korz W, Sykes TR, Sykes CJ, Hör G, McEwan AJ, and Noujaim AA (1997) Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients. Nucl Med Commun 18:878-886.
19. Nicodemus CF and Berek JS (2005) Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 5:87-96.
20. Noujaim AA, Schultes BC, Baum RP, and Madiyalakan R (2001) Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16:187-203.
21. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, and York L (2001) The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 22:348-366.
22. Pimm MV (1995) Circulating antigen: bad or good for immunoscintigraphy? Nucl Med Biol 22:137-145.
23. Pimm MV, Durrant LG, and Baldwin RW (1989) Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model. Eur J Cancer Clin Oncol 25:1325-1332.
24. Piver MS, Baker TR, Piedmonte M, and Sandecki AM (1991) Epidemiology and etiology of ovarian cancer. Semin Oncol 18:177-185.
25. Polakis P (2005) Arming antibodies for cancer therapy. Curr Opin Pharmacol 5:382-387.
26. Potchoiba MJ, Tensfeldt TG, Nocerini MR, and Silber BM (1995) A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther 272:953-962.
27. Potchoiba MJ, West M, and Nocerini MR (1998) Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labeled xenobiotics. Drug Metab Dispos 26:272-277.
28. 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunol Immunother 47:39-46.
29. Regoeczi E (1987) Iodine Labeled Plasma Protein, vol II, part B, pp 645-648, CRC Press, Boca Raton, FL.
30. Sakahara H, Hosono M, Kobayashi H, Yao Z, Saga T, Yano S, Endo K, Mori T, and Konishi J (1996) Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-CA125 monoclonal antibody. Jpn J Cancer Res 87:655-661.
31. Schultes BC, Baum RP, Niesen A, Noujaim AA, and Madiyalakan R (1998) Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 46:201-212.
32. Steinke W, Archimbaud Y, Becka M, Binder R, Busch U, Dupont P, and Maas J (2000) Quantitative distribution studies in animals: cross-validation of radioluminography versus liquid-scintillation measurement. Regul Toxicol Pharmacol 31:S33-S43.
33. Trail PA, King HD, and Dubowchik GM (2003) Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52:328-337.
34. Ullberg S and Larsson B (1981) Whole-body autoradiography. Methods Enzymol 77:64-80.
35. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, and Kenemans P (1999) CA 125: fundamental and clinical aspects. Semin Cancer Biol 9:117-124.
36. Wu AM and Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146.
37. Yin BW and Lloyd KO (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371-27375. (Pubitemid 37410652)